New CAR t therapy targets tough ovarian cancers in early trial

NCT ID NCT06469281

First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 27 times

Summary

This early-phase study tests an experimental treatment called 27T51, a type of CAR T cell therapy that targets a protein (MUC16) found on certain cancer cells. It is for women with recurrent or hard-to-treat ovarian, peritoneal, or fallopian tube cancer. The study has two parts: first, finding a safe dose, and then testing that dose alone or with other drugs. About 90 participants will take part to see if this approach is safe and can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • John Theurer Cancer Center Hackensack University Medical Center

    RECRUITING

    Hackensack, New Jersey, 07601, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • LDS Hospital

    RECRUITING

    Salt Lake City, Utah, 84143, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-••••

  • Roswell Park Cancer Institute

    RECRUITING

    Buffalo, New York, 14203, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UPMC Hillman Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.